Clinical

Dataset Information

0

A prospective observational study evaluating intestinal microbiome as a biomarker to predict the efficacy and toxicity of prostate cancer patients receiveing PARP inhibitors alone or combined with novel ADT agents

ABSTRACT: Interventions: case series:None Primary outcome(s): side effects Study Design: Sequential

DISEASE(S): Prostate Cancer

PROVIDER: 2707329 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical A prospective observational study evaluating intestinal microbiome as a biomarker to predict the efficacy and toxicity of BRCA1/2 mutant metastatic castration resistant prostate cancer patietns receiveing PARP inhibitors
| 2695487 | ecrin-mdr-crc
Unknown ARHGEF38 as a novel biomarker to predict aggressive prostate cancer.
| S-EPMC7083745 | biostudies-literature
Unknown Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
| S-EPMC7402352 | biostudies-literature
Unknown PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
| S-EPMC8380207 | biostudies-literature
Unknown Prostate Cancer Nodal Staging: Using Deep Learning to Predict 68Ga-PSMA-Positivity from CT Imaging Alone.
| S-EPMC7042227 | biostudies-literature
Unknown Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.
| S-EPMC5880088 | biostudies-literature
Unknown Novel agents in the management of castration resistant prostate cancer.
| S-EPMC4007389 | biostudies-other
Unknown BET inhibitors as novel therapeutic agents in breast cancer.
| S-EPMC5642636 | biostudies-literature
Unknown Novel heteroaryl phosphonicdiamides PTPs inhibitors as anti-hyperglycemic agents.
| S-EPMC4305230 | biostudies-literature
Unknown Cell toxicity mechanism and biomarker.
| S-EPMC6206310 | biostudies-other